Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors

NCT03650348 is registered in ClinicalTrials.gov with Pieris Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03650348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03650348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors
Lead sponsor
Pieris Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 21, 2018
Completion date
August 11, 2022
Enrollment
41 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive bladder cancer, her2-positive breast cancer, her2-positive gastric cancer, her2-positive solid tumor